OliX Pharmaceuticals Company Description

OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.

The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis.

The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA.

OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.

OliX Pharmaceuticals, Inc

Country	South Korea
Founded	2010
Industry	Biological Products, Except Diagnostic Substances
Employees	72
CEO	Dong-Ki Lee

Contact Details

Address: Ace Gwanggyo Tower1 Suwon-si, 16226 South Korea
Phone	82 3 1779 8400
Website	olixpharma.com

Stock Details

Ticker Symbol	226950
Exchange	Korea Exchange - KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
SIC Code	2836

Key Executives

Name	Position
Dong-Ki Lee	Chief Executive Officer
Jin Kim Young	Chief Financial Officer